#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #PediatricIndications #Adalimumab #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=86225
Celltrion Secures Additional Pediatric Indications for Yuflyma in US
Celltrion has received FDA approval for additional pediatric indications of Yuflyma in the US, targeting pediatric uveitis and hidradenitis suppurativa, and aims to expand its market presence as exclusivity for the original drug expires.